Quarterly ResultMay 7, 2026, 04:04 PM
Xenon Pharma Q1: Azetukalner Phase 3 Positive, NDA Q3 2026; Cash $1.3B
AI Summary
Xenon Pharmaceuticals reported positive topline data from its Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), exceeding expectations and paving the way for an NDA submission in Q3 2026. The company also reported Q1 2026 financial results, with cash, cash equivalents, and marketable securities totaling $1.34 billion as of March 31, 2026, extending its cash runway into 2029. While net loss increased to $102.3 million, this was primarily due to increased R&D expenses for ongoing clinical programs, including five additional Phase 3 studies for azetukalner and early-stage pain candidates.
Key Highlights
- Azetukalner Phase 3 X-TOLE2 met primary endpoint in FOS, showing -53.2% and -34.5% seizure reduction.
- Anticipates submitting a New Drug Application (NDA) for azetukalner in Q3 2026.
- Cash, cash equivalents, and marketable securities totaled $1.34 billion as of March 31, 2026.
- Cash runway extended into 2029, supported by $130.0M ATM and $707.6M public offering.
- Net loss for Q1 2026 was $102.3 million, compared to $65.0 million in Q1 2025.
- Research and development expenses increased to $88.5 million in Q1 2026 from $61.2 million in Q1 2025.
- Phase 3 X-NOVA2 MDD topline data is expected in H1 2027.
- Phase 1 studies for XEN1701 and XEN1120 for pain are expected to complete in H2 2026.